Chromosomal aberrations during cell division represent one of the first recognized features
of human cancer cells, and modern detection methods have revealed the pervasiveness of …

Chronic myeloid leukemia (CML) has been regarded as the paradigmatic example of a
malignancy defined by a unique molecular event, the BCR-ABL1 oncogene. Decades of …

The BCR-ABL1 oncoprotein transforms pluripotent HSCs and initiates chronic myeloid
leukemia (CML). Patients with early phase (also known as chronic phase [CP]) disease …

Targeted therapy in the form of selective tyrosine kinase inhibitors (TKI) has transformed the
approach to management of chronic myeloid leukemia (CML) and dramatically improved …

Inhibition of an initiating oncogene often leads to extensive tumour cell death, a
phenomenon known as oncogene addiction. This has led to the search for compounds that …

We performed a multi-institutional retrospective analysis of the morphologic features,
immunophenotype, cytogenetics, and BCR-ABL transcript characterization of cases of …

Additional chromosomal abnormalities (ACAs) in Philadelphia-positive cells have been
reported in∼ 5% of patients with newly diagnosed chronic myeloid leukemia (CML) in …

Imatinib mesylate (IM), an original Abl tyrosine kinase inhibitor, entered the clinics in 1998
for the treatment of patients with chronic myeloid leukemia (CML). The drug is universally …

Tyrosine-kinase inhibitors have changed the natural history of chronic myeloid leukaemia in
such a way that patients with adequate access to these agents, who are properly managed …

BACKGROUND: Nilotinib is a selective, potent BCR‐ABL inhibitor. Previous studies
demonstrated the efficacy and safety of nilotinib in Philadelphia chromosome‐positive …